Antiobesity medications tirzepatide and semaglutide offer long-term health benefits but are not cost-effective.

Despite substantial health benefits, two GLP-1 receptor agonists weren't cost-effective at their current prices, according to ...

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and ...

Tirzepatide — a drug that acts both as a GLP-1 agonist and a GIP agonist — is the active ingredient in an even more powerful ...

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...

USA: A recent economic evaluation has highlighted the significant long-term health benefits of tirzepatide and semaglutide in ...

Since starting on the compounded tirzepatide, Christina says ... The standard forms of Zepbound, which come in an ...

Wegovy is also available through NovoCare Pharmacy, which directly ship all dose strengths at a cost of $499 per month for ...

Among all antiobesity medications, the incremental cost-effectiveness ratios were $197,023 and $467,676 per quality-adjusted life-year for tirzepatide and semaglutide, respectively. HealthDay News ...